Abstract
Somatostatin receptor imaging (SRI) was performed in five patients with known non-functioning pituitary adenomas. To determine whether the pituitary uptake correlates with response to octreotide therapy, an uptake index (UI) was calculated. Pituitary adenomas were detected in all five patients. The UI was, respectively, 15.1, 3.7, 2.2, 2.2 and 2.2 (the UI calculated in 12 normal subjects was between 1 and 1.9). Only the patient with the highest Ul (15.1) had a dramatic improvement in tumour volume and visual function in response to octreotide therapy. The Ul might be a good predictive parameter of octreotide therapy efficacy in non-functioning adenomas.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Reubi JC, Heitz PU, Landolt AM. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 1987;65: 65–73.
Bertherat J, Brue T, Enjalbert A, et al. Somatostatin (SRIH) receptors on thyrotropin (TSH)-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab 1992;75: 540–546.
Levy A, Eckland DJA, Gurney AM, Reubi JC, Doshi R, Lightman SL. Somatostatin and thyrotropin-releasing hormone response and receptor status of a thyrotropin-secreting pituitary adenoma, clinical and in vitro studies. J Neuroendocrinol 1989;1: 321–326.
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, van Hagen M, Postema PTE, de Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ, Koper JW, Lamberts SWJ. Somatostatin receptor scintigraphy with (111In-DTPA-D-Phe1)-and (123I-Tyr3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20: 716–729.
Nocaudie M, Huglo D, Deveaux M, Proye C, Marchandise X. Scintigraphie à lïode 123-Tyr-3-octréotide et attitudes thérapeutiques. A propos de trois cas. Médecine Nucléaire, Imagerie fonctionnelle et métabolique 1993;17: 74–80.
Ikuyama S, Nawata H, Kato K, et al. Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab 1985;61: 666–671.
Spada A, Reza-Elahi F, Lania A, Del Alamo P, Basetti M, Faglia G. Alterations in receptor status and postreceptor events in human pituitary tumors. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A, eds. Pituitary adenomas: new trends in basic and clinical research. Amsterdam: Elsevier Science; 1991: 95–102.
Faglia G, Spada A, Beck-Peccoz P, Persani L, Ambrosi B, Colombo P. Clinically nonfunctioning adenomas: advaences and perspectives. In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A, eds. Pituitary adenomas: new trends in basic and clinical research. Amsterdam: Elsevier Science; 1991: 373–382.
Lahlou N, Le Nestour E, Chanson P, et al. Inhibin and follicle-stimulating hormone levels in gonadotroph adenomas: evidence of a positive correlation with tumour volume in men. Clin Endocrinol 1993;38: 301–309.
Klibanski A, Alexander JM, Bikkal HA, Hsu DW, Swearingen B, Zervas NT. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. J Clin Endocrinol Metab 1991;73: 1248–1255.
Plöckinger U, Fett U, Bader M, Reichel M, Koppenhagen K, Wolf KJ, Quabbe HJ. Preoperative octreotide therapy of GH-secreting and endocrine inactive pituitary adenomas. Proceedings of the 75th Annual Meeting of the Endocrine Society, Las Vegas, Nevada, 9–12 June 1993 (abstract 75).
Warnet A, Timsit J, Chanson P, et al. The effect of somatostatin analogue on chiasmal dysfunction from pituitary adenomas. J Neurosurg 1989;71: 687–690.
Rünzi M, Jaspers C, Benker G, et al. Dramatische Besserung eines Chiasmasyndromes bei endokrin inaktivem Makroadenom der Hypophyse unter Therapie mit dem Somatostatinanalogon SMS 201-995 [abstract]. Klin Wochenschr 1989;67 Suppl 16: 284.
De Bruin TWA, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SWJ, Croughs RIM. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab 1992;75: 1310–1317.
Liuzzi A, Dallabonzana D, Oppizzi G, Arrigoni GL, Cozzi R, Strade S, Benini Z, Chiodini J, Chiodini PG. Is there a real medical treatment for “non secreting” pituitary adenomas? In: Faglia G, Beck-Peccoz P, Ambrosi B, Travaglini P, Spada A, eds. Pituitary adenomas: new trends in basic and clinical research. Amsterdam: Elsevier Science; 1991: 383–390.
Gasperi M, Petrini L, Pilosu R, Nardi M, Marcello A, Mastio F, Bartalena L, Martino E. Octreotide treatment does not affect the size of non-secreting pituitary adenomas. J Endocrinol Invest 1993;16: 541–543.
Bazzoni N, Farabola M, Arosio M, Casati G, Faglia G. Is the effect of octreotide therapy in patients with functionless pituitary adenomas predictable [abstract]? J Endocrinol Invest 1991;14 Suppl 2: 53.
Turpin G, Foubert L, Noël-Weckstein S, Kujas M, de Gennes JL. Adénome somatotrope silencieux. Effet anticephalique d'un analogue de la somatostatine (octréotide). Sem Hôp Paris 1991;67: 1967–1969.
Warnet A, Harris AG, Renard E, James-Didier A, Chaumet-Riffaud P and the French Sandostatin Pituitary Tumor group. Octreotide therapy of nonfunctioning and gonadotroph adenomas.
Renard E, Barjon JN, Bringer J, Frerebeau P, Jaffiol C. Efficacité précoce de la sandostatine (SMS 201-995) sur le retentissement visuel des tumeurs hypothalamo-hypophysaires non secrétantes étendues [abstract]. Ann Endocrinol (Paris) 1989;50: 260.
Losa M, Ducati A, Fava E, Cenzato M, Giovanelli M. Postoperative acute administration of octreotide to patients with tumors of the sellar region can induce improvement of residual defects of visual function [abstract]. J Endocr Invest 1991;14 Suppl 4: 214.
Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12: 450–482.
Muhr C, Bergstrom M, Lundberg P, Bergström K, Lungström B. Positron emission tomography for the in vivo characterization and follow-up of treatment in pituitary adenomas. In: Landolt AM, Hefzt PU, Zapf J, Girard J, del Pazoe E, eds. Advances in pituitary adenoma research. Oxford: Pergamon Press; 1988: 163–170.
Author information
Authors and Affiliations
Additional information
Correspondence to: I. Virgolini, Department of Nuclear Medicine, University of Vienna, Währinger Gürtel 18–20, A-1090 Vienna, Austria
Rights and permissions
About this article
Cite this article
Duet, M., Mundler, O., Ajzenberg, C. et al. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. Eur J Nucl Med 21, 647–650 (1994). https://doi.org/10.1007/BF00285587
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00285587